.jpg?w=340&itok=CfGKIdSx "EPR in healthcare news."){kind=icon}
Heart failure is one of the leading causes of hospitalisation among adults over 65. Cardiovascular outcome trials can be complex and costly. Find out how considering the human element of CVOTs, and building appropriate...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Strategies for commercialising oncology treatments for young adults
This article explores the imperatives and strategies for commercialising oncology treatments targeting young adults, highlighting the need for innovative regulatory and commercial strategies to ensure successful market entry and improved patient outcomes.
-
Survey shows varied views on impact of new cancer drugs
This article published in The Pharma Letter highlights findings from an ICON survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
-
Innovation and flexibility in long-term follow-up studies
Read insights from Harpreet Gill VP, Real World Solutions, on how sponsors can optimise their LTFU studies to be flexible and cost-effective, with strategic planning and innovation, overcoming challenges while capturing valuable data insights.
-
Biomarker Identification a Challenge and Opportunity in Cancer Drug Development, Survey Finds
This news piece from Precision Medicine Online provides an overview of the findings from ICON’s recent survey of professionals engaged in oncology-related clinical research. It shares respondents' insights on how precision medicine approaches are changing development strategies and the to the extent these therapeutic advances will benefit patients in the future.
-
Navigating oncology development decisions for long-term success
In this media article, ICON expert Tanja Obradovic, PhD, highlights how mapping clear inflection points for data-driven decisions will inform efficient drug development.
-
Overcoming Challenges in the Development of Antibody Drug Conjugates
In this article, ICON’s Andreas Dreps reviews the innovations that have helped ADCs overcome clinical development challenges.
-
Engineering CAR T-cell sharpshooters
In this article, ICON's Brian Huber explains why and discusses the prospects for the next-generation of CAR T-cell therapies engineered to be more adaptable, precise and controlled.
-
.jpg?w=545&itok=D64BxPTu "EPR in healthcare news.")
Application of NGS to enhance the molecular monitoring of CML patients
This Q&A with Dr Jin Li and Dr Chad Galderisi of ICON Specialty Laboratory Solutions discusses ICON’s development of its RNA-based next generation sequencing (NGS) assay that detects mutations in chronic myeloid leukemia (CML) and how it can benefit both routine clinics and clinical trial settings.
-
Clinical development strategy in oncology
In Dr Tanja Obradovic's article in The Cancer Letter, she discusses how to navigate early clinical development and support robust registrational strategy and late-stage development in oncology.
-
From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress
In this article, ICON’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
